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Introduction  
The aim of this paper is to explore the ethical issues on why boys are not currently included 
in the Human Papilloma Virus vaccination schedule in the United Kingdom (UK). There is a 
paucity of literature on the benefits of vaccinating boys (Hull and Caplan, 2009).The current 
vaccination schedule in the UK for the Human Papilloma Virus (HPV) offers a two dose 
quadrivalent vaccination (against HPV types 6, 11, 16 and 18) for adolescent girls between 
11-13 years old. This is given as a school based programme and is only offered to girls 
(NHS Choices). Boys are currently not offered the vaccine and there are no current plans to 
do so.  
 
Background  
The vaccine was first introduced in the UK in 2008 (Green Book, 2014) with the intention of 
preventing sexually transmitted disease in girls (Bennett, 2016). However, mass 
immunisation of girls raises ethical dilemmas that can affect boys, which this paper will 
address (Hann and Peckham, 2008). HPV is a group of viruses that affect the skin and moist 
mucus membranes in any sex (NHS, 2016). As a DNA virus the organs most at risk are the 
cervix in girls and the mouth in both boys and girls (Peate, 2009). There are over one 
hundred subtypes of HPV however there are four that are known to cause significant 
disease. Subtypes 16 and 18 are known to cause approximately 70% of cancers of the 
cervix. Subtypes 6 and 11 being the leading causative factor in the most common genital 
warts.  
 
HPV is a very common virus, 80% of the adult population have genital HPV virus at some 
point in their life with over 80% of sexually active women being infected during their lifetime 
(Trottier and Burchell, 2009). HPV can develop after skin to skin (genital) contact and is not 
a result of penetrative sex only. The majority of people who become infected with HPV will 
not have any symptoms; the immune system will clear the virus in the majority of healthy 
people. In some people, however, the immune system cannot clear the virus; this is more 
common in people who are affected by HIV/AIDS or who are immunosuppressed (Russell et 
al 2013). There are also people with no known immunological problems whose immune 
systems do not clear the virus although it is not known why this occurs (Green Book 2014).  
Brisson et al (2011) acknowledge that HPV causes a substantial burden of disease in 
females. However, they also describe the disease being problematic to males. In fact, there 
has been a rise in the incidence of oropharyngeal cancers, particularly in men (Ramqvist and 
Dalianis, 2010). Gillison et al (2012) report a significant increase in the incidence of 
oropharyngeal squamous cell carcinomas over the past 30 years with HPV has being cited 
as the underlying cause. Furthermore, the rate of anal cancer is increasing among both men 
and women (Palefsky et al 2011). In spite of this, boys are not covered by the national HPV 
vaccination programme. Kim et al (2007) suggest that this is due entirely to cost with 
Pearson et al (2014) reporting that herd immunity is best achieved by improving the 
coverage of vaccination of girls rather than vaccinating boys as individuals. However, HPV 
vaccination is a public matter for all and is ethically complex due to challenges that public 
health has on best practice versus economic resources and as such it raises significant 
ethical issues Baun et al (2007).  
 
 
 
Ethical Issues  
Beauchamp and Childress (2013) describe four principles of biomedical ethics which are 
considered culturally neutral to enable practitioners to think and consider ethical issues in 
health care. The three principles that this paper will consider are: beneficence which is the 
action should be in the best interest of the patient or to do good; non maleficence is that the 
action should do no harm and justice and equality concerning whether the action is equal 
and fair.  
 The Duty to Do Good  
Beneficence concerns doing good and averting harm (Purtillo, 2005). It is well documented 
that the HPV vaccination has prevented common cancers including genital warts (Bennet, 
2016) and is therefore effective and is of benefit to the target population (Munoz et al 2010). 
The vaccine efficacy is proven by the PATRICIA (PApilloma TRIal against Cancer in young 
Adults) trial (Lehtinen et al 2011). This was a large, double blind, randomised study to 
determine the vaccine efficacy at preventing cervical intraepithelial neoplasia (CIN). CIN is 
abnormal cells in the squamous epithelium of the cervix that are proven to be a precursor to 
malignant disease. The results of the trial were that high coverage of the target population 
may have the potential to significantly impact on the rates of cervical cancer as vaccine 
efficacy against CIN3+ (highest level) that was caused by HPV type 16 or 18 was 100%. 
This is supported by Markowitz et al (2013) as a result of their analysis of prevalence data of 
HPV in the pre and post vaccine eras. Their conclusion was that the vaccine effectiveness 
was estimated to be high as despite low coverage and the uptake of all doses being low the 
reduction in disease was 56%. These studies by Munoz et al, Lehtinen et al and Markowitz 
et al demonstrate that the vaccine is effective and in the best interests of the target cohort 
(girls aged 12-13) and as the risk of cervical cancer is significantly reduced.  
 
There is also evidence to suggest that the vaccine also has value in preventing disease 
caused by HPV in males. A large randomised, double blind, placebo controlled trial was 
completed by Giuliano et al (2011) with the intention to determine whether quadrivalent HPV 
vaccination was as effective in males to prevent subsequent disease after becoming infected 
with HPV as it was in females. The results were that the vaccine did prevent infection with 
HPV and suggested that vaccine efficacy may be similar for the two sexes. Palefsky (2011) 
carried out a sub study of a larger double blind study to determine if HPV vaccine could be 
effective in reducing the rates of anal cancer in men who have sex with men. A reduction in 
the incidence of anal cancer in this sub group was observed.  
 The further studies by Giuliano et al and Palefsky demonstrate that the vaccine is of benefit 
to the population, not just the current target cohort of girls. The vaccine does reduce the 
incidence of CIN and therefore subsequent risk of malignant disease of the cervix. The 
vaccine also reduces the incidence of genital warts. This is further supported by Bauer at al 
(2011) who claim the vaccine significantly reduces the risk of genital warts in both males and 
females. The Nobel Peace Prize winner Harald Zuf Hausen who won the prize in 2008 for 
his discovery in the 1980’s that HPV causes cervical cancer has called for boys to be added 
to the current vaccination schedule. He theorises that vaccinating boys will protect them as 
individuals but also prevent transmission to unvaccinated partners. This approach 
demonstrates the clear benefit of vaccinating boys as well as girls (Branković et al, 2013).  
Therefore, the principle of beneficence which is further described by Fry and Johnstone 
(2008) as helping others gain what is beneficial to them and an action that will actively 
promote their wellbeing can be applied to the scenario of the HPV vaccine being routinely 
offered to boys. The evidence suggests that there is a clear benefit to boys as well as girls. 
Moreover, Luyten et al (2014) remark whether it is ethically justifiable not to vaccinate boys 
as well as girls. They argue that there is a duty not to harm others as those not afforded the 
opportunity to have the vaccine can clearly be harmful to not only themselves, but others 
whom they have sexual contact with who may not have had the vaccine also. Nonetheless, 
the status quo remains in the UK in that vaccination will be for girls only.  
In the United States of America the HPV vaccination was offered to boys in 2011 (Sokley et 
al, 2014). The Centre for Disease Control and Prevention (CDC) state that HPV vaccination 
is recommended for boys at age 11-12; furthermore, they suggest that there will also be 
benefit to girls by reducing the spread of HPV (CDC, 2015). Australia followed by adding 
boys to their HPV vaccination programme in 2013 to protect the boys as individuals but also 
to improve herd immunity where vaccination uptake and coverage may be low (Australian 
department of Health, 2015). Arguably, both countries programmes are beneficial and are in 
the best interests of all of the population who are vaccinated. Furthermore, it has the 
potential to improve herd immunity for the unvaccinated population. A view shared by Luyten 
et al (2014) who argues that vaccinating boys will have a significant impact on girls as they 
are more at risk of catching the disease.  
 
The Duty Not to Harm Others  
Vaccination is an extremely effective public health intervention, second only to clean water 
for the impact there is on saving lives and promoting good health (Yarwood 2014). However, 
conversely, vaccinations are drugs and as with all drugs, there is always a risk that the 
vaccine has the potential to cause harm as well as do good. Accordingly, when any drug or 
vaccination is prescribed it must always be considered if the benefits outweigh the risk of 
harm. The duty of non-maleficence is a difficult principle to apply to vaccinations as the 
ethical duty to not cause harm, is seen to be stronger than the duty of beneficence which is 
to do good (Chonko 2012). Further, it is multifaceted with the aim to prevent disease and 
illness and at the same time promote health and well-being (Bennet, 2016).  
 
Concerns have been raised that the HPV vaccination causes harm. Although rare, Haug 
(2009) documented that there were reports of anaphylaxis, Guillain Barre Syndrome, 
demyelinating diseases, pancreatitis and thromboembolic events after vaccination and 
suggested a causal link. In a recent study by Scheller et al (2015) it was acknowledged that 
reports have suggested a link between multiple sclerosis and other demyelinating diseases. 
However, these concerns have been disproved as there appears to be no increased risk in 
receiving the vaccine from the earlier research by Slade et al (2009). Adverse reactions are 
rare, often reversible and despite this the evidence strongly suggests that the HPV vaccine 
is safe and that the benefits far outweigh the minimal risk of harm (Kuehn, 2011).  
 
Fairness and Justice  
This principle ensures that individuals should be treated equally and fairly (Beauchamp and 
Childress 2013). This can be interpreted as a right of every individual to be able to access 
available resources based on their health care needs within the area they live. There should 
not be any cost disadvantages for the less well off (Malmqvist et al, 2011). In the following 
this principle, according to Gorin et al (2011) it is unfair for boys not to enjoy the same 
benefits as girls who are routinely vaccinated. Boys have equal health needs as girls as they 
are equally at risk of developing disease from HPV infection; there should not be any health 
disparity between sexes (Bakir and Skarzynski, 2015). Arguably, they should therefore 
receive equal health resources such as the HPV vaccination, which is currently only afforded 
to girls (Fry and Johnstone 2008). Clearly, however, this does not happen in the UK and that 
boy and girls are not treated the same regarding the HPV vaccine. Justice alone therefore 
fails to take into account whether implementation is politically feasible or acceptable by a 
particular community (Malmqvist et al, 2011). Gorin et al (2011) further mention, although the 
vaccine is effective, it is costly and therefore it can be seen as a financial barrier to counties 
offering it to boys as well as girls.  
 
Conversely, Brisson et al (2011) argue that health needs between boys and girls are not 
equal; where HPV causes a substantial burden of disease in girls it does so to a much lesser 
extent in boys. Although, boys and girls are both at significant risk of disease from HPV the 
evidence suggests that the risk is greater for girls. Mortensen (2015) comments that girls 
have a more direct benefit in having the vaccine than boys to prevent cervical cancer as 
opposed to boys who have more of an indirect benefit. However, an aspect of justice is 
fairness, whether an action is fair to all concerned. In this situation whether it is fair that boys 
are currently only protected from HPV by proposed herd immunity. Protecting boys from 
HPV by herd immunity alone may not entirely represent fairness (Branković el al, 2013). 
Boys as individuals have a right to their own protection from HPV. However, arguments tend 
to focus on boys having the vaccine to protect girls as opposed to protecting themselves 
from cancers such as penile or anal cancer, which is perhaps unbalanced, not truly 
informative and unfair (Foresta, 2009). This view is supported by Professor John Ashton 
CBE, President of the Faculty of Public Health who stated that although the decisions about 
protecting children and adults against cancer should be made on the evidence and not on 
moral judgements, it is not acceptable to withhold effective health interventions from males 
simply on the grounds of gender (Ashton, 2016).  
 
This question of men who have sex with men can also be raised. There is no herd immunity 
available for this group of males. Anal cancer rates are increasing in both males and females 
but particularly in men who have sex with men (MSM) (Palefsky et al 2011). However, the 
Joint Committee on Vaccination and Immunisation (JCVI) released an interim statement in 
November 2014 reporting that the HPV vaccination for MSM is to become available but not 
for boys. The programme will be targeted at 16-45 year old males who identify themselves 
as MSM, via genitourinary medicine and HIV clinics. The problem that arises from protecting 
males in this manner is that it is very difficult to ascertain when a man knows he is gay. If a 
man realises he is gay and receives the vaccination prior to any sexual contact, this 
programme would be successful for that cohort; however, it can be argued that sexual 
contact with another male may be what determines for the male that he is gay/bisexual, by 
which time it is potentially too late to protect against HPV.  
 
Optimal protection from HPV vaccination only occurs if it is administered before first sexual 
contact (HPV Action 2016). Men who have sex with men do not benefit from the current 
vaccination schedule, the vaccine is available to them on an individual basis. However this 
would be unnecessary if adolescent boys were routinely offered the vaccination. It would 
remove gender health inequalities and place the responsibility for good sexual health with 
the individual rather than with just females or men who have sex with men (HPV Action 
2016).  
 
The option is available for an adolescent boy to access the HPV vaccination privately at the 
request of and paid for by his parents or guardians, this is available at over 40 clinics in the 
UK (What Clinic, 2016). This promotes further health inequalities between richer and poorer 
social groups, which HPV Action (2016) raise the concern that existing inequalities in cancer 
will be further exacerbated. This is clearly not just, equal nor fair.  
 
Conclusion  
The risks that males could potentially develop disease relating to infection with HPV are well 
documented and are considered significant (Brisson et al 2011 and Palefsky et al 2011). The 
evidence suggests that the benefit of being protected from HPV by vaccination clearly 
outweigh any risk that the vaccine may carry; therefore vaccinating boys can be considered 
as beneficial (Scheller et al 2015) (Arnheim-Dahlström et al, 2013). However, health needs 
of males and females are not equal; females are at greater risk of developing disease 
related to HPV but even so, the risks to males are significant enough to demonstrate that 
males also need protecting from the virus (Cancer Research UK 2012). The evidence 
suggests that the differences in risk are not substantial enough to justify not including boys in 
the HPV vaccination programme merely due to their gender. There is potential that adding 
boys to the UK schedule would improve herd immunity, offer protection for unvaccinated 
women and place the burden of ensuring good sexual health equally between males and 
females (HPV Action 2014). The current programme which is based on cost effectiveness 
and suggests that boys will receive protection by herd immunity is not satisfactory as there 
are pockets of society where vaccination levels are low therefore herd immunity is not 
available to males or females in these areas.  
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